WO2006007510A1 - Compositions and methods for treating eye disorders and conditions - Google Patents
Compositions and methods for treating eye disorders and conditions Download PDFInfo
- Publication number
- WO2006007510A1 WO2006007510A1 PCT/US2005/023113 US2005023113W WO2006007510A1 WO 2006007510 A1 WO2006007510 A1 WO 2006007510A1 US 2005023113 W US2005023113 W US 2005023113W WO 2006007510 A1 WO2006007510 A1 WO 2006007510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- omega
- composition
- fatty acid
- acid
- eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0512864A BRPI0512864B8 (en) | 2004-07-01 | 2005-06-30 | ophthalmic composition, use of at least one omega-6 fatty acid and at least one omega-3 fatty acid and method for preparing said composition |
EP05767809.6A EP1781278B2 (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
MX2007000208A MX2007000208A (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions. |
CA002572344A CA2572344A1 (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
JP2007520365A JP2008505177A (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
AU2005262392A AU2005262392A1 (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
NZ552481A NZ552481A (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
IL180342A IL180342A0 (en) | 2004-07-01 | 2006-12-26 | Compositions and methods for treating eye disorders and conditions |
NO20070561A NO20070561L (en) | 2004-07-01 | 2007-01-30 | Compositions and Methods for Treating Eye Diseases and Conditions. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58451404P | 2004-07-01 | 2004-07-01 | |
US60/584,514 | 2004-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006007510A1 true WO2006007510A1 (en) | 2006-01-19 |
Family
ID=35784207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/023113 WO2006007510A1 (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060009522A1 (en) |
EP (1) | EP1781278B2 (en) |
JP (1) | JP2008505177A (en) |
KR (1) | KR20070040381A (en) |
CN (1) | CN101043884A (en) |
AU (1) | AU2005262392A1 (en) |
BR (1) | BRPI0512864B8 (en) |
CA (1) | CA2572344A1 (en) |
IL (1) | IL180342A0 (en) |
MX (1) | MX2007000208A (en) |
NO (1) | NO20070561L (en) |
NZ (1) | NZ552481A (en) |
RU (1) | RU2007103835A (en) |
WO (1) | WO2006007510A1 (en) |
ZA (1) | ZA200700918B (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007130960A2 (en) * | 2006-05-03 | 2007-11-15 | Advanced Medical Optics, Inc. | Stable ophthalmic oil-in-water emulsions with omega-3 fatty acids for alleviating dry eye |
ITRM20090119A1 (en) * | 2009-03-19 | 2010-09-19 | Medivis S R L | OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS. |
WO2012059158A1 (en) | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Composition and drug containing omega-3 fatty acids, and a modulator |
US20130005805A1 (en) * | 2011-06-30 | 2013-01-03 | Annabelle Gallois-Bernos | Esters for treatment of ocular inflammatory conditions |
EP2664330A1 (en) | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Composition and medication containing Omega 3 fatty acids and a glucosaminoglucan |
WO2014041071A1 (en) | 2012-09-12 | 2014-03-20 | Novaliq Gmbh | Semifluorinated alkane compositions |
US9308262B2 (en) | 2011-05-25 | 2016-04-12 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
EP2437762B1 (en) | 2009-06-05 | 2017-08-09 | Allergan, Inc. | Artificial tears and therapeutic uses |
US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
US9757459B2 (en) | 2010-10-20 | 2017-09-12 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2584415A1 (en) * | 2004-10-19 | 2006-04-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Topical treatment with ngf and dha in damaged corneas |
US20070293410A1 (en) * | 2006-06-15 | 2007-12-20 | Surowiak Richard J | Contact lens and method for preventing contact lens intolerance |
EP2211881A4 (en) * | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
US20110200645A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Free Fatty Acid Emulsions |
WO2011103514A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha triglyceride emulsions |
US20110200644A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Ester Emulsions |
CN103221041B (en) * | 2010-11-19 | 2016-08-03 | 日本水产株式会社 | For corneal epithelium pathological changes and/or the therapeutic agent of conjunctival epithelium pathological changes or preventive |
WO2012145119A2 (en) * | 2011-04-17 | 2012-10-26 | Michael Gurin | Low inflammatory blended oils |
US9381183B2 (en) * | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
US20160310456A1 (en) * | 2013-03-12 | 2016-10-27 | Physicians Recommended Nutriceuticals, Llc | Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure |
CA2845868C (en) * | 2011-09-12 | 2018-11-06 | Tassos GEORGIOU | Use of epa and dha in treating occular disorder |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
EP3072510B1 (en) | 2012-03-30 | 2019-05-08 | Micelle BioPharma, Inc. | Omega-3 fatty acid ester compositions |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
WO2014035450A1 (en) * | 2012-08-31 | 2014-03-06 | Bausch & Lomb Incorporated | Ophthalmic compositions with omega-3 fatty acids |
US8673325B1 (en) * | 2012-09-06 | 2014-03-18 | Dignity Sciences Limited | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
WO2014132162A1 (en) | 2013-02-26 | 2014-09-04 | Belkin Laser Ltd. | System for glaucoma treatment |
US20150080329A1 (en) * | 2013-09-19 | 2015-03-19 | Dignity Sciences Limited | Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof |
BR112016028518A2 (en) | 2014-06-04 | 2017-08-22 | Dignity Sciences Ltd | pharmaceutical compositions comprising dgla and use thereof |
NZ732058A (en) | 2014-11-25 | 2023-06-30 | Allergan Inc | Stabilized omega-3 ophthalmic compositions |
WO2016094876A1 (en) * | 2014-12-12 | 2016-06-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
CN112245420A (en) | 2015-07-21 | 2021-01-22 | 艾菲穆恩有限公司 | Compositions comprising 15-HEPE for treating or preventing cancer and neurological diseases |
CN106963728A (en) * | 2016-01-13 | 2017-07-21 | 汤欣 | A kind of preparation method and applications of docosahexaenoic acid subconjunctival injection liquid |
WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
NO345574B1 (en) * | 2018-06-19 | 2021-04-26 | Epax Norway As | Composition for treatment of dry eye disease and meibomianitis |
AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
WO2021148845A1 (en) * | 2020-01-23 | 2021-07-29 | Visufarma S.P.A. | Ophthalmic composition for the treatment of dry eye disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911944A (en) * | 1987-08-19 | 1990-03-27 | Holub Bruce J | Animal feed supplement |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US437014A (en) * | 1890-09-23 | Swing | ||
US3572913A (en) * | 1969-02-03 | 1971-03-30 | Boylston Res Ass | Comprehensive support for ophthalmic examination apparatus and instruments |
US4401372A (en) * | 1972-10-02 | 1983-08-30 | Syntex (U.S.A.) Inc. | Contact lens |
US4180308A (en) * | 1972-10-02 | 1979-12-25 | Syntex (Usa) Inc. | Contact lens |
US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
US4056496A (en) * | 1972-10-02 | 1977-11-01 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
DE2309440A1 (en) * | 1973-02-26 | 1974-09-05 | Katz | METHOD OF ISOLATING LYSOZYME |
US3991759A (en) | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
US4202226A (en) * | 1978-02-06 | 1980-05-13 | SyntexLaboratories, Inc. | Method and apparatus for manufacturing plastic lenses |
US4313355A (en) * | 1978-02-06 | 1982-02-02 | Syntex (U.S.A.) Inc. | Method and apparatus for manufacturing plastic lenses |
US4338419A (en) * | 1979-02-09 | 1982-07-06 | Syntex (U.S.A.) Inc. | Process for treatment of hydrogel lens with thiols |
US4379864A (en) * | 1979-02-09 | 1983-04-12 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
US4267295A (en) * | 1979-02-09 | 1981-05-12 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
US4543371A (en) * | 1981-03-05 | 1985-09-24 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
US5145686A (en) * | 1982-02-03 | 1992-09-08 | Efamol Limited | Topical pharmaceutical compositions |
ATE24266T1 (en) | 1982-04-16 | 1987-01-15 | Nestle Sa | LIPID COMPOSITION FOR ORAL, ENTERAL OR PARENTERAL NUTRITION. |
US4421748A (en) * | 1982-07-13 | 1983-12-20 | Trager Seymour F | Artificial tear aid |
US4678698A (en) * | 1983-04-12 | 1987-07-07 | Minnesota Mining And Manufacturing Company | Contact lens cleaning article |
US4622258A (en) * | 1983-04-12 | 1986-11-11 | Minnesota Mining And Manufacturing Company | Contact lens cleaning article |
US4533399A (en) * | 1983-04-12 | 1985-08-06 | Minnesota Mining And Manufacturing Company | Contact lens cleaning method |
JPS6158539A (en) * | 1984-08-29 | 1986-03-25 | Nisshin Oil Mills Ltd:The | Preparation of snack-like cake |
US4613380A (en) * | 1985-04-01 | 1986-09-23 | Dow Corning Corporation | Method for removing lipid deposits from contact lenses |
US5484432A (en) * | 1985-09-27 | 1996-01-16 | Laser Biotech, Inc. | Collagen treatment apparatus |
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US5017370A (en) * | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
US4997644A (en) * | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
US5047236A (en) * | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5032394A (en) * | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
US5089260A (en) * | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5240701A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of performing angioplasty procedures |
US5250294A (en) * | 1986-05-15 | 1993-10-05 | Emory University | Improved perfusion medium for transplantation of organs |
US5078995A (en) * | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
US5080894A (en) * | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US5648071A (en) * | 1986-05-15 | 1997-07-15 | Emory University | Method of treating tumors |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5028599A (en) * | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US4801452A (en) * | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
US4837014A (en) * | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5240702A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of treating stroke |
US5064643A (en) * | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
US4937070A (en) * | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
US4914088A (en) * | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
US5278151A (en) * | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
GB8710780D0 (en) * | 1987-05-07 | 1987-06-10 | Scras | Opthalmological application of eicosapentaenoic acid |
US5111221A (en) * | 1988-05-13 | 1992-05-05 | United States Of America As Represented By The Secretary Of The Navy | Receptor-based sensor |
US5225374A (en) * | 1988-05-13 | 1993-07-06 | The United States Of America As Represented By The Secretary Of The Navy | Method of fabricating a receptor-based sensor |
US4923700A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Artificial tear suspension |
US4959048A (en) * | 1989-01-17 | 1990-09-25 | Helix Medical, Inc. | Lacrimal duct occluder |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5278142A (en) * | 1989-03-20 | 1994-01-11 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
US5206298A (en) * | 1989-12-19 | 1993-04-27 | Tomei Sangyo Kabushiki Kaisha | Graft copolymer, solution containing the graft copolymer for treating contact lens, and method of treating contact lens with the solution and making hydrophilic lens surface |
ZA912797B (en) * | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
EP0459148B1 (en) * | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
US5167323A (en) * | 1990-08-09 | 1992-12-01 | Tomei Sangyo Co., Ltd. | Lens treating device for treating contact lens |
US5181604A (en) * | 1990-09-14 | 1993-01-26 | Tomei Sangyo Co., Ltd. | Contact lens holder and treating device |
US5203337A (en) * | 1991-05-08 | 1993-04-20 | Brigham And Women's Hospital, Inc. | Coronary artery imaging system |
ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
US5469867A (en) * | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
PH30249A (en) * | 1992-09-16 | 1997-02-05 | Zhejiang Provincial Hospital O | Neutral lipids from endosperm of job's tears |
JPH06122627A (en) * | 1992-10-13 | 1994-05-06 | Sagami Chem Res Center | Antiallergic instillation |
US5378488A (en) * | 1993-06-10 | 1995-01-03 | Abbott Laboratories | Aseptic processing of infant formula |
AU1520095A (en) * | 1993-12-29 | 1995-07-17 | Bausch & Lomb Incorporated | Carbohydrate composition and method for cleaning and disinfecting contact lenses |
US6060644A (en) * | 1994-03-24 | 2000-05-09 | Iowa State University Research Foundation, Inc. | Isolation and use of cuticular lipid genes |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
US5861148A (en) * | 1995-01-23 | 1999-01-19 | Smith; Stewart Gregory | Ophthalmic compositions and process of using |
US6113894A (en) * | 1995-01-23 | 2000-09-05 | Smith; S. Gregory | Ophthalmic compositions and process of using |
EP0733918B1 (en) * | 1995-03-24 | 2003-07-30 | Ocular Research of Boston, Inc. | Hydrogel lens pre-coated with lipid layer |
US5738856A (en) * | 1995-11-03 | 1998-04-14 | Ocular Research Of Boston, Inc. | Skin care preparation and method |
WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
BR9711019A (en) * | 1996-08-02 | 1999-08-17 | Plum Kemi Prod | Oil-in-water emulsion for use on human skin for cleaning, preserving or improving the condition of the skin |
BR9710402A (en) * | 1996-09-20 | 1999-08-17 | Altherogenics Inc | Diagnosis for and mediators of inflammatory disorders |
US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
JPH10218760A (en) | 1997-02-04 | 1998-08-18 | Nobel Igaku Kenkyusho:Kk | Eye drop with small amount of oil added for treating dry eye |
AU6631298A (en) * | 1997-03-03 | 1998-09-22 | Adcock Ingram Limited | A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease |
US6107365A (en) * | 1997-09-03 | 2000-08-22 | The Regents Of The University Of California | Biomimetic hydrogel materials |
US6475784B1 (en) * | 1997-11-14 | 2002-11-05 | Valentis, Inc. | Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides |
US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
AU754064B2 (en) | 1998-05-15 | 2002-11-07 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drops |
US6346594B1 (en) * | 1998-09-21 | 2002-02-12 | Menicon Co., Ltd. | Ocular lens material and process for producing same |
ES2255987T3 (en) * | 1999-03-01 | 2006-07-16 | Milcin Therapeutics Llc | OPHTHALMIC PREPARATIONS CONTAINING MUCINE. |
US6429194B1 (en) * | 1999-03-01 | 2002-08-06 | Vista Scientific Llc | Mucin containing ophthalmic preparation |
US6428502B1 (en) * | 1999-06-25 | 2002-08-06 | Alcon Manufacturing, Ltd. | Punctal cannula |
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
AUPQ228199A0 (en) | 1999-08-18 | 1999-09-09 | Sly, Anthony William | Ophthalmic fluid |
EP1408930A1 (en) * | 1999-10-20 | 2004-04-21 | Vesifact Ag | Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions |
US6286955B1 (en) * | 1999-12-15 | 2001-09-11 | Tetsuya Sakai | Biocompatible lens, and method of producing the same |
US6344047B1 (en) * | 2000-02-02 | 2002-02-05 | Eagle Vision | Instrument for inserting a punctum plug and method for manufacturing the instrument |
US6533415B2 (en) * | 2000-03-21 | 2003-03-18 | Menicon Co., Ltd. | Ocular lens material having hydrophilic surface and process for preparing the same |
GB0012597D0 (en) * | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
WO2002009803A1 (en) * | 2000-08-01 | 2002-02-07 | Ocular Research Of Boston, Inc. | Visual discomfort relief |
US6506412B2 (en) | 2000-11-29 | 2003-01-14 | Sciencebased Health | Treatment of dry eye syndrome |
US6667047B2 (en) * | 2001-07-27 | 2003-12-23 | International Flute Technologies Ltd | Ultra-stable composition comprising moringa oil and its derivatives and uses thereof |
CA2458146C (en) * | 2001-08-23 | 2012-07-24 | Westgate Biological Limited | Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
US20040076691A1 (en) | 2002-01-16 | 2004-04-22 | David Haines | Anti-inflammatory formulations |
US20040048926A1 (en) * | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
AU2003238240A1 (en) * | 2002-06-17 | 2003-12-31 | Resolvyx Pharmaceuticals | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
WO2004006801A2 (en) | 2002-07-17 | 2004-01-22 | Biosyntrx, Inc. | Treatment for dry eye syndrome |
US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
JP2005008570A (en) * | 2003-06-19 | 2005-01-13 | Santen Pharmaceut Co Ltd | Agent for treating corneal disease |
US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
-
2005
- 2005-06-30 CA CA002572344A patent/CA2572344A1/en not_active Abandoned
- 2005-06-30 AU AU2005262392A patent/AU2005262392A1/en not_active Abandoned
- 2005-06-30 NZ NZ552481A patent/NZ552481A/en unknown
- 2005-06-30 KR KR1020077002456A patent/KR20070040381A/en not_active Application Discontinuation
- 2005-06-30 EP EP05767809.6A patent/EP1781278B2/en not_active Not-in-force
- 2005-06-30 RU RU2007103835/15A patent/RU2007103835A/en not_active Application Discontinuation
- 2005-06-30 JP JP2007520365A patent/JP2008505177A/en active Pending
- 2005-06-30 WO PCT/US2005/023113 patent/WO2006007510A1/en active Application Filing
- 2005-06-30 MX MX2007000208A patent/MX2007000208A/en not_active Application Discontinuation
- 2005-06-30 US US11/171,815 patent/US20060009522A1/en not_active Abandoned
- 2005-06-30 CN CNA2005800287299A patent/CN101043884A/en active Pending
- 2005-06-30 BR BRPI0512864A patent/BRPI0512864B8/en not_active IP Right Cessation
-
2006
- 2006-12-26 IL IL180342A patent/IL180342A0/en unknown
-
2007
- 2007-01-30 NO NO20070561A patent/NO20070561L/en not_active Application Discontinuation
- 2007-01-31 ZA ZA200700918A patent/ZA200700918B/en unknown
- 2007-10-17 US US11/873,478 patent/US20080153909A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911944A (en) * | 1987-08-19 | 1990-03-27 | Holub Bruce J | Animal feed supplement |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007130960A2 (en) * | 2006-05-03 | 2007-11-15 | Advanced Medical Optics, Inc. | Stable ophthalmic oil-in-water emulsions with omega-3 fatty acids for alleviating dry eye |
WO2007130960A3 (en) * | 2006-05-03 | 2008-05-22 | Advanced Medical Optics Inc | Stable ophthalmic oil-in-water emulsions with omega-3 fatty acids for alleviating dry eye |
ITRM20090119A1 (en) * | 2009-03-19 | 2010-09-19 | Medivis S R L | OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS. |
WO2010106571A2 (en) | 2009-03-19 | 2010-09-23 | Medivis S.R.L. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
WO2010106571A3 (en) * | 2009-03-19 | 2010-11-18 | Medivis S.R.L. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
CN102355889A (en) * | 2009-03-19 | 2012-02-15 | Trb化药国际股份有限公司 | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
RU2545675C2 (en) * | 2009-03-19 | 2015-04-10 | Трб Чимедика Интернэшнл С.А. | Ophthalmological composition, based on polyunsaturated fatty acids omega-3 and omega-6 |
US8957110B2 (en) | 2009-03-19 | 2015-02-17 | Trb Chemedica International S.A. | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
US11045515B2 (en) | 2009-06-05 | 2021-06-29 | Allergan, Inc. | Artificial tears and therapeutic uses |
EP2437762B1 (en) | 2009-06-05 | 2017-08-09 | Allergan, Inc. | Artificial tears and therapeutic uses |
US10525062B2 (en) | 2010-03-17 | 2020-01-07 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US11324757B2 (en) | 2010-03-17 | 2022-05-10 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US9757459B2 (en) | 2010-10-20 | 2017-09-12 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
US9968678B2 (en) | 2010-10-20 | 2018-05-15 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
DE102010050570A1 (en) | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Composition and medicaments containing ω-3 fatty acids and an inhibitor of NF-κB transcription factor |
WO2012059158A1 (en) | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Composition and drug containing omega-3 fatty acids, and a modulator |
US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
US9308262B2 (en) | 2011-05-25 | 2016-04-12 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
US10813999B2 (en) | 2011-05-25 | 2020-10-27 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
US11844836B2 (en) | 2011-05-25 | 2023-12-19 | Dermaliq Therapeutics, Inc. | Topical pharmaceutical composition based on semifluorinated alkanes |
US20210379005A1 (en) * | 2011-06-30 | 2021-12-09 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
US11096919B2 (en) | 2011-06-30 | 2021-08-24 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
US11311510B2 (en) | 2011-06-30 | 2022-04-26 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
US20130005805A1 (en) * | 2011-06-30 | 2013-01-03 | Annabelle Gallois-Bernos | Esters for treatment of ocular inflammatory conditions |
US10588887B2 (en) | 2011-06-30 | 2020-03-17 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
US10383839B2 (en) * | 2011-06-30 | 2019-08-20 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
USRE49758E1 (en) | 2012-01-23 | 2023-12-19 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
EP2664330A1 (en) | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Composition and medication containing Omega 3 fatty acids and a glucosaminoglucan |
WO2013171203A1 (en) | 2012-05-15 | 2013-11-21 | F. Holzer Gmbh | Fluid dispenser containing an ophthalmological composition |
US10576154B2 (en) | 2012-09-12 | 2020-03-03 | Novaliq Gmbh | Semifluorinated alkane compositions |
US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
US10449164B2 (en) | 2012-09-12 | 2019-10-22 | Novaliq Gmbh | Methods of treating ocular disorders using semifluorinated alkanes |
EP3488847A1 (en) | 2012-09-12 | 2019-05-29 | Novaliq GmbH | Semifluorinated alkane compositions |
US9770508B2 (en) | 2012-09-12 | 2017-09-26 | Novaliq Gmbh | Semifluorinated alkane compositions |
EP3181119A1 (en) | 2012-09-12 | 2017-06-21 | Novaliq GmbH | Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca |
DE202013012753U1 (en) | 2012-09-12 | 2019-03-04 | Novaliq Gmbh | Compositions of semifluorinated alkanes for use in the treatment of keratoconjunctivitis Sicca |
WO2014041071A1 (en) | 2012-09-12 | 2014-03-20 | Novaliq Gmbh | Semifluorinated alkane compositions |
US10058615B2 (en) | 2012-09-12 | 2018-08-28 | Novaliq Gmbh | Semifluorinated alkane compositions |
US11583513B2 (en) | 2012-09-12 | 2023-02-21 | Novaliq Gmbh | Semifluorinated alkane compositions |
EP4342537A2 (en) | 2012-09-12 | 2024-03-27 | Novaliq GmbH | Semifluorinated alkane compositions |
US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
US11357738B2 (en) | 2015-09-30 | 2022-06-14 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
US11400132B2 (en) | 2016-09-23 | 2022-08-02 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
Also Published As
Publication number | Publication date |
---|---|
EP1781278B2 (en) | 2019-10-16 |
EP1781278A1 (en) | 2007-05-09 |
BRPI0512864B8 (en) | 2021-05-25 |
CA2572344A1 (en) | 2006-01-19 |
KR20070040381A (en) | 2007-04-16 |
ZA200700918B (en) | 2008-10-29 |
AU2005262392A1 (en) | 2006-01-19 |
US20080153909A1 (en) | 2008-06-26 |
EP1781278B1 (en) | 2016-08-10 |
EP1781278A4 (en) | 2009-09-02 |
BRPI0512864A (en) | 2008-04-08 |
CN101043884A (en) | 2007-09-26 |
MX2007000208A (en) | 2007-08-07 |
US20060009522A1 (en) | 2006-01-12 |
IL180342A0 (en) | 2007-07-04 |
NO20070561L (en) | 2007-03-30 |
BRPI0512864B1 (en) | 2021-04-27 |
NZ552481A (en) | 2008-12-24 |
RU2007103835A (en) | 2008-08-10 |
JP2008505177A (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1781278B2 (en) | Compositions and methods for treating eye disorders and conditions | |
US20070265341A1 (en) | Compositions and methods for treating eye disorders and conditions | |
KR101677308B1 (en) | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids | |
Mohamed et al. | Current trends in pharmaceutical treatment of dry eye disease: A review | |
JP6675361B2 (en) | Esters for treating ocular inflammatory conditions | |
López-Cano et al. | Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection | |
EP3280395B1 (en) | Ophthalmic compositions based on polyunsaturated fatty acids and triacylglycerols | |
JP2022506684A (en) | Artificial tears | |
WO2023055321A1 (en) | Anti-inflammatory microemulsion eye formulations derived from nigella sativa oil | |
TR2021015389A2 (en) | MICROEMULSION EYE FORMULATIONS WITH ANTI-INFLAMMATORY EFFECT FROM BLACK SEED OIL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2572344 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180342 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3932/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005262392 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500022 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007520365 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552481 Country of ref document: NZ Ref document number: MX/a/2007/000208 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2005767809 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005767809 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005262392 Country of ref document: AU Date of ref document: 20050630 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005262392 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077002456 Country of ref document: KR Ref document number: 200700918 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20070107 Country of ref document: BY Ref document number: 9842 Country of ref document: GE Ref document number: 2007103835 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580028729.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005767809 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 20070107 Country of ref document: BY |
|
ENP | Entry into the national phase |
Ref document number: PI0512864 Country of ref document: BR |